Agreement signed at the Abu Dhabi Future Health Summit 2026, attended by the South Korean ambassador to the UAE, the Burjeel Holdings chairman, and other key figures
Pilot deployment and clinical validation using anonymized data to begin; comprehensive assessment of diagnostic accuracy and workflow utility underway

(From left) George Thomas, Head of Cardiology at Virgil Hospital Abu Dhabi; Ashiq Moideen, Director of Virgil Hospital Abu Dhabi; Shamsheer Vayalil, Chairman of Virgil Holdings; Kim Junghee, CEO of ALPI; Lee Wonik, Ambassador of the Republic of Korea to the UAE; and Park Jisun, Director of the Korean Pavilion at Virgil Hospital Abu Dhabi, pose for a commemorative photo after a signing ceremony at the Abu Dhabi Future Health Summit 2026. (Photo courtesy of ALPI)

(From left) George Thomas, Head of Cardiology at Virgil Hospital Abu Dhabi; Ashiq Moideen, Director of Virgil Hospital Abu Dhabi; Shamsheer Vayalil, Chairman of Virgil Holdings; Kim Junghee, CEO of ALPI; Lee Wonik, Ambassador of the Republic of Korea to the UAE; and Park Jisun, Director of the Korean Pavilion at Virgil Hospital Abu Dhabi, pose for a commemorative photo after a signing ceremony at the Abu Dhabi Future Health Summit 2026. (Photo courtesy of ALPI)

View original image

ALPI Co., Ltd. (CEO Kim Junghee) announced that it signed a memorandum of understanding (MoU) with Burjeel Hospital Abu Dhabi on October 21 (local time) at the Abu Dhabi Future Health Summit 2026, held in the United Arab Emirates (UAE). The agreement aims to conduct local clinical validation and pilot deployment of ECG Buddy, an AI-powered electrocardiogram (ECG) interpretation support solution.


In the presence of Lee Wonik, South Korea’s ambassador to the UAE, and Shamsheer Vayalil, chairman of Burjeel Holdings, the agreement was signed by Ashiq Moideen, director of Burjeel Hospital Abu Dhabi, and ALPI CEO Kim Junghee.


Burjeel Hospital Abu Dhabi is part of Burjeel Holdings, a major private healthcare group in the UAE. The hospital is expanding its advanced capabilities, recently becoming the first in the Gulf Cooperation Council (GCC) region to introduce an AI-powered cardiac catheterization laboratory (Cath Lab). The agreement is part of the Burjeel Group’s innovation strategy, “Burjeel 2.0,” which seeks to strengthen clinical excellence and accelerate decision-making.


Under the agreement, the two organizations will pilot ECG Buddy at Burjeel Hospital Abu Dhabi and launch retrospective and prospective clinical validation studies using de-identified, anonymized ECG data. The studies will assess diagnostic accuracy, sensitivity and specificity, workflow efficiency, and clinical utility to rigorously demonstrate ECG Buddy’s performance in the local healthcare environment.


To this end, they will establish a joint working group of experts in clinical care, research, regulatory affairs, IT, and business. The group will lead the study design, review clinical workflows, analyze local regulatory requirements, and oversee subsequent steps. The organizations will also explore close collaboration between Korean and UAE medical and technology experts, including joint clinical research, academic publications, and knowledge exchange.


ECG Buddy uses AI to analyze ECGs, identify heart rhythm abnormalities such as arrhythmia, and provide additional information on cardiovascular disease risks, supporting medical professionals’ interpretation and clinical judgment. Because initial ECG interpretation often shapes a patient’s entire cardiac care journey, the solution is designed to help medical professionals make more reliable decisions at the initial assessment stage.


AI solutions that rapidly analyze large volumes of data to identify signs of cardiac abnormalities play an important role in addressing physician shortages and securing the golden hour in emergencies.


ECG Buddy is a Class II digital medical device approved by the Ministry of Food and Drug Safety (MFDS) (D Jeheo 24-1179) and has obtained CE marking under the European Union Medical Device Regulation (EU MDR 2017/745). In South Korea, it has been adopted by around 150 hospitals and analyzes more than 300,000 ECGs each month.


“Our collaboration with Burjeel Hospital is an important opportunity to apply AI-powered ECG interpretation technology in a new clinical setting and assess its potential to support cardiovascular care,” said ALPI CEO Kim Junghee. “By combining ALPI’s technological capabilities with Burjeel’s advanced clinical expertise, we will build meaningful clinical evidence and jointly explore how AI can help medical professionals identify cardiovascular risks and make decisions. We aim to contribute to the advancement of AI-powered cardiac diagnostics in the Middle East.”


“In cardiac care, decisions made during the initial assessment can shape a patient’s entire care journey. AI can help medical professionals identify key diagnostic signals earlier and make better-informed decisions,” said George Thomas, head of cardiology and an interventional cardiologist at Burjeel Hospital Abu Dhabi. “However, any technology must undergo rigorous validation and be responsibly integrated into existing care pathways to deliver real clinical value. Through this collaboration, we will work to ensure that innovation leads to earlier detection, timely intervention, and better patient outcomes.”


“South Korea has made significant advances in medical technology and clinical innovation, and this collaboration is an opportunity to bring that expertise to the UAE,” said Park Jisun, director of the Korean Pavilion at Burjeel Hospital Abu Dhabi and an orthopedic specialist. “Building on the close ties between the healthcare systems of the two countries, we will jointly explore how AI technology developed in South Korea can support clinical practice, strengthen knowledge exchange, and improve patient care across the region.”


The two organizations agreed to explore expansion across Burjeel Group hospitals and identify additional business opportunities in the GCC and Middle East and North Africa (MENA) regions, subject to clinical results, local regulatory approval, and mutually agreed terms. ALPI, which obtained Saudi Food and Drug Authority (SFDA) marketing authorization (MDMA) this October, plans to expand its presence in the Middle East based on local evidence, following its expansion into South Korea, Europe, Australia, Vietnam, and Taiwan. In addition to ECG Buddy, ALPI offers ECG Buddy Clinic for screening and ECG Buddy Research for research. More information is available on the company’s official website, and inquiries can be sent by email.



The agreement is significant because it creates an opportunity for ALPI’s technology, validated through MFDS approval, European CE certification, and adoption by around 150 hospitals in South Korea, to establish a foothold in the Middle East through a partnership with a leading UAE hospital, following its SFDA authorization in Saudi Arabia. Backed by government diplomatic support and cooperation among experts from both countries, the pilot deployment and research will build local clinical evidence and could serve as a practical bridge to broader adoption of the solution across the Burjeel Group and throughout the GCC and MENA regions.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing